

Address: 6776 Southwest Freeway Suite STE# 620 Houston, TX 77074 CLIA – 45D1061571 | Lab Director - Albert Chen M.D. Phone: 281-378-2116 | Fax: 281-466-2483

RESPIRATORY PATHOGEN PANEL TESTING REQUISITION FORM

Please attach the following documents with this test order

Medical Necessity
 SOAP Notes
 Visit History Notes

Patient Care-plan
 Medication List, if any

		PATIENT	INFORMATION			
Patient First Name		Patient Last Name			Biological Sex 🗌 F	М
Date of Birth (MM/DD/YYYY)	Phone Number		Email		Social Security Number	
Address		City	Sta	te Zip		
Ethnicity: 🗌 African American	🗌 Asian 🔲 Ca	ucasian 🗌 H	lispanic 🗌 Jewish(Ashkenaz	i) 🗌 Port	uguese Other	
PATIENT INSURANCE INFORMATION Attach patient demographics and copy of insurance card				SPECIMEN INFORMATION Respiratory Nasopharynx Swab		
Insurance Self-Pay Client Bill			PRACTICE INFORMATION			
Name of the insurance Secondary Insurance, If any				Provider Name: Practice/Facility Name:		
Insurance Policy/ID number	Name of the ins	ured	City, State, Zip:	Address: City, State, Zip:		
Insurance Group number	Date of Birth of	Insured	NPI # # (optional):	Phone:Fax:Fax:Fax:Fax:		
	•	TEST F	PANEL			
RPPRPP (Continued)Influenza A virusMetapneumovirus (MPV)Influenza B virusBocavirus (HBoV)Respiratory Syncytial Virus A (RSV A)Rhinovirus (HRV)Respiratory Syncytial Virus B (RSV B)Coronavirus NL63 (CoV NL63)Flu A-H1Coronavirus 229E (CoV 229E)Flu A-H1pdm09Coronavirus OC43 (CoV OC43)Flu A-H3Streptococcus PneumoniaeAdenovirus (AdV)Mycoplasma PneumoniaeEnterovirus (HEV)Chlamydophila PneumoniaeParainfluenza Virus 2 (PIV 2)Haemophilus InfluenzaeParainfluenza Virus 3 (PIV 3)Bordetella ParapertussisParainfluenza Virus 4 (PIV 4)Bordetella Parapertussis		Carbapenem-resistant E Klebsiella Pneumoniae Ca Verona Integron-Mediated New Delhi Metallo Beta La Imipenem Resistant Pseud Oxacillinase (OXA-48) Vancomycin Resistant En Vancomycin Resistant Gen Extended Spectrum Beta	ANTIBIOTIC RESISTANCE PANEL Carbapenem-resistant Enterobacteriaceae (CRE) Klebsiella Pneumoniae Carbapenemase (KPC) Verona Integron-Mediated Metallo Beta Lactamase (VIM) New Delhi Metallo Beta Lactamase (NDM) Imipenem Resistant Pseudomonas (IMP) Oxacillinase (OXA-48) Vancomycin Resistant Enterococci (VRE). Vancomycin Resistant Gene A (VAN A) Vancomycin Resistant Gene B (VAN B) Extended Spectrum Beta Lactamase (ESBL) Cefotaxime Resistant Munich (CTX-M)			
DIAGNOSIS (I	CD-10) CODES Se	elect or write-ir	n one or more codes from the	spaces/se	lections below (REQUIRED)	
 J02.9 - Acute pharyngitis, unspecified J04.0 Acute laryngitis J06.9 - Acute upper respiratory infection, unspecified J12.9 - Viral pneumonia, unspecified R05.1 - Acute cough R07.81 - Pleurodynia R50.9 Fever, unspecified B97.29 - Other coronavirus cause of diseases classified elsewhere J04.2 - Acute laryngotracheitis J18.0 - Bronchopneumonia, unspecified organism J45.40 - Moderate persistent asthma, uncomplicated J45.998 - Other sthma R04.2 - Hemoptysis R06.1 Stridor R07.1 - Chest pain on breathing R68.83 Chills (without fever) Z03.818 - Encounter for observation for suspected exposure J18.9 - Pneumonia, unspecified organism J44.0 - Chronic pulmonary disease with (acute) lower respiratory J44.1 - Chronic pulmonary disease with (acute) exacerbation J45.50 - Severe persistent asthma, uncomplicated J45.991 - Cough variant asthma J47.1 - Bronchiectasis with (acute) exacerbation J47.9 - Bronchiectasis, uncomplicated 		 J15.8 - Pneumonia due to other specified bacteria J16.8 - Pneumonia due to other specified infectious organisms J12.0 - Adenoviral pneumonia J18.2 - Hypostatic pneumonia, unspecified organism J18.8 - Other pneumonia, unspecified organism J20.8 - Acute bronchitis due to other specified organisms J22 - Unspecified acute lower respiratory infection J41.0 - Simple chronic bronchitis J41.1 - Mucopurulent chronic bronchitis J41.8 - Nixed simple and mucopurulent chronic bronchitis J43.0 - Unilateral pulmonary emphysema [MacLeod's syndrome] J43.1 - Panlobular emphysema J43.2 - Centrilobular emphysema J43.3 - Other emphysema J45.22 - Mild intermittent asthma with status asthmaticus J45.31 - Mild persistent asthma with (acute) exacerbation J45.41 - Moderate persistent asthma with (acute) exacerbation J45.42 - Moderate persistent asthma with status asthmaticus 		LIS 147 170 184 190 184 195 195 	 52 - Severe persistent asthma with status asthm 0 - Bronchiectasis with acute lower respiratory 0.3 - Chronic drug-induced interstitial lung disor 1.115 - Respiratory bronchiolitis interstitial lung. 1.12 - Influenza due to identified novel influenza 1.10 - Pulmonary fibrosis, unspecified 1.112 - Idiopathic pulmonary fibrosis 1.114 - Acute interstitial pneumonitis 5.03 - Acute respiratory distress 3.1 - Weakness 5.0 - Acute obstructive laryngitis [croup] 5.10 - Acute epiglotitis with obstruction 5.11 - Acute apiglotitis with obstruction 5.11 - Acute rasopharyngitis 1.1 - Acute tracheitis with obstruction 5.10 - Acute racheitis with obstruction 5.11 - Acute tracheitis with obstruction 5.11 - Acute tracheitis with obstruction 5.12 - Acute fibrosis with obstruction 5.13 - Acute racheitis with obstruction 5.14 - Acute tracheitis with obstruction 5.15 - Syncope and collapse 6.10 - Acute apiglotitis with obstruction 5.11 - Acute tracheitis with obstruction 5.13 - Acute fibrosis with obstruction 5.14 - Acute tracheitis with obstruction 5.15 - Syncope and collapse 6.10 - Acute fibrosis with obstruction 5.10 - Acute tracheitis with obstruction 5.11 - Acute tracheitis with obstruction 5.10 - Acute fibrosis with obstruction 5.10 - Cystic fibrosis with other intestinal manifestatic 5.19 - Cystic fibrosis with other ranifestations 5.21 - Secondary pulmonary arterial hypertensic 	v infection rders I disease ta A virus
 J12.82 - Pneumonia due to coronavirus disease 2019 J12.89 - Other viral pneumonia 		J45.51 - Severe persistent asthma with (acute) exacerbation		🗆 I27	□ 127.24 - Chronic thromboembolic pulmonary hypertension □ 127.29 - Other secondary pulmonary hypertension	

PATIENT CONSENT AUTHORIZATION

I hereby assign all rights and benefits under my health plan and all rights and obligations that I and my dependents have under my health plan to **Elite Clinical Laboratory** its assigned affiliates and authorized representatives for laboratory services furnished to me by **Elite Clinical Laboratory** I irrevocably designate, authorize and appoint **Elite Clinical Laboratory** or its assigned affiliates and their authorized representatives as my true and lawful attorney-in-fact for the purpose of submitting my claims, obtain a copy of my health plan document, Summary Plan Description, disclosure, appeal, litigation or other remedies in accordance with the benefits and rights under my health plan and in accordance with federal or state laws. If my health plan fails to abide by my authorization and makes payment directly to me, I agree to endorse the insurance check and forward it to **Elite Clinical Laboratory** immediately upon receipt. I hereby authorize **Elite Clinical Laboratory** its assigned affiliates and authorized representatives to contact me or my health Plan/administrator for billing or payment purposes by phone, text message, or email with the contact information that I have provided to **Elite Clinical Laboratory**, in compliance with federal and state laws. **Elite Clinical Laboratory** its assigned affiliates and their authorized representatives may release to my health plan administrator, my employer, and my authorized representative my personal health information for the purpose of procuring payment of **Elite Clinical Laboratory** and for all the laboratory services. I understand the acceptance of insurance does not relieve me from any responsibility concerning payment for laboratory services and that I am financially responsible for all charges whether or not they are covered by my insurance.

Signature of Patient or Patient Representative / Relationship to Patient:

Date:

PROVIDER INFORMATION

As part of my antibiotic stewardship policy, I find it medically necessary to rapidly determine and differentiate a viral and/or bacterial infection in order to treat with or without appropriate antibiotics. Having the most accurate and timely data available to me directly guides my treatment and patient management. Empiric treatment and management leads to inappropriate and unnecessary antibiotic use (50% according to the CDC) and delayed diagnosis which can lead to severe consequences. Standard antibody/antigen detection is only available to detect few pathogens and comes with a high false negative rate, relatively lower sensitivity (60-70%) and specificity (80-90%). In addition, standard antibody/antigen detection requires the infection to be present for days allowing the body to make ample antibodies in order to detect. Qualitative Nucleic Acid Amplification Testing (NAAT) is far superior with sensitivities and specificities > 98% and available to detect many pathogens. In addition, NAAT has built in controls to determine if an adequate patient sample was collected and processed, therefore greatly reducing false negative results. NAAT also includes controls to easily determine a contaminated sample, therefore reducing false positive results.

Ordering Physician Signature:

Date: